assay · intermediate · partly written
Caco-2 permeability assay
A human colon-cancer cell line grown as a tight sheet on a filter is dosed on one side and the drug appearing on the other side gives apparent permeability and an efflux ratio.
Also called: Caco-2
How well it predicts more
In four single-laboratory datasets of at least 23 drugs each, 68 percent +/- 14 percent of drugs were classified correctly by the BCS cut (at least 90 percent absorbed), with all high-permeability drugs correct and low-permeability drugs correct for 56 percent +/- 15 percent; the r-squared for absorption was -0.693, 0.0757, 0.912 and 0.702 across the sets, very uneven between laboratories. A 14-drug study found a log-linear fit to human fraction absorbed with R-squared 0.805 for Caco-2 versus 0.664 for Franz-cell PAMPA. 12
Reported, not yet replicated
Practical limits and the regulatory use more
The vendor lists low recovery, plastic binding and cell trapping as making Papp and efflux calls ambiguous, an efflux ratio that can fall under 2 and miss a pump substrate, and BCRP confounding P-gp calls (MDCK-MDR1 suggested for P-gp). ICH M9 allows Caco-2 for high-permeability claims only if passive transport is shown, with at least five model drugs per permeability class plus a zero marker. 34
Reported, not yet replicated
Question answered
Readout physical
Drug amount on the receiving side over time, giving Papp = (dQ/dt) / (C0 x A) in 1e-6 cm/s, in both directions; the efflux ratio is Papp(B-A)/Papp(A-B) and a value above 2 flags an efflux pump. 3
Reported, not yet replicated
Not measured
Transporters the cells lack and the paracellular route; hydrophilic transporter substrates such as amiloride, cephalexin, levodopa and zidovudine were discussed as false positives across PAMPA and Caco-2. A high Papp says a drug can cross a cell sheet, not that the oral dose will be bioavailable. 1
Reported, not yet replicated
Setting
Where in cascade
Sample prep
Cells are grown 18 to 22 days on a porous filter; the compound is dosed on one side for 2 hours. 3
Reported, not yet replicated
Still open here
- Cost and throughput with basis and date.
- The 2023 review correlation (R = 0.95) was a secondary figure and is not held.
Not yet written: Conditions, Throughput class, Throughput, Time per run, Cost, Engineerable variants, Use cases, Before after, Capital, Emerging, ML role, Data availability.
Linked from
Sources
- Larregieu CA, Benet LZ. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol Pharm (2014). paper; opened 2026-11-17 all records citing this
- de Souza Teixeira L, Vila Chagas T, Alonso A, Gonzalez-Alvarez I, et al.. Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. Pharmaceutics (2020). paper; opened 2026-11-17 all records citing this
- Caco-2 permeability assay (Evotec). Evotec. vendor-page, not peer reviewed; opened 2026-11-17 all records citing this
- ICH M9: Biopharmaceutics Classification System-based biowaivers, Step 5. ICH, via PMDA (2020). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/assays/caco-2-permeability-assay.json